Search

Displaying results 1731 - 1740 of 4539 in total
  1. Drug

    Upinitatug rilsodotin

    go.drugbank.com/drugs/DB19104
    Investigational

    Upinitatug rilsodotin is under investigation in clinical trial NCT05329545 (Upifitamab Rilsodotin Maintenance in Platinum-sensitive Recurrent Ovarian Cancer (UP-NEXT)).

  2. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

  3. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

  4. Drug

    Prednicarbate

    go.drugbank.com/drugs/DB01130
    Approved

    It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.

  5. Drug

    Furaprevir

    go.drugbank.com/drugs/DB12785
    Investigational

    Furaprevir is under investigation in clinical trial NCT01523990 (A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients).

  6. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists.

  7. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow.

  8. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [A263481] Sotatercept was approved by the European Commission on August 26, 2024.[L51549] … [L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).

  9. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L12789] It was later approved by Health Canada on 30 April 2010. … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].

  10. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.